Literature DB >> 23741252

(-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells.

Kengo Ogawa1, Takeshi Hara, Masahito Shimizu, Junji Nagano, Tomohiko Ohno, Masato Hoshi, Hiroyasu Ito, Hisashi Tsurumi, Kuniaki Saito, Mitsuru Seishima, Hisataka Moriwaki.   

Abstract

Immune escape, the ability of tumor cells to avoid tumor-specific immune responses, occurs during the development and progression of several types of human malignancies, including colorectal cancer (CRC). Indoleamine 2,3-dioxygenase (IDO), the tryptophan catabolic enzyme, plays a significant role in regulating the immune response and provides tumor cells with a potent tool to evade the immune system. In the present study, we examined the effects of (-)-epigallocatechin gallate (EGCG), the major catechin in green tea, on the inhibition of IDO expression induced by interferon (IFN)-γ in human CRC cells. We found that IFN-γ increased the expression levels of IDO protein and mRNA in HT29 and SW837 CRC cell lines. Treatment of SW837 cells with EGCG significantly decreased IFN-γ-induced expression of IDO protein and mRNA in a dose-dependent manner. Enzymatic activity of IDO, determined by the concentration of L-kynurenine in the culture medium, was also significantly inhibited by EGCG treatment. Phosphorylation of signal transducer and activator of transcription 1 (STAT1) induced by IFN-γ was also significantly inhibited by EGCG. Reporter assays indicated that EGCG inhibited the transcriptional activities of IDO promoters, IFN-stimulated response element and IFN-γ activation sequence, activated by STAT1 phosphorylation. These findings suggest that EGCG may exert antitumor effects on CRC, at least in part, by inhibiting the expression and function of IDO through the suppression of STAT1 activation. EGCG may, thus, serve as a potential agent for antitumor immunotherapy and be useful in the chemoprevention and/or treatment of CRC.

Entities:  

Keywords:  (-)-epigallocatechin gallate; 3-dioxygenase; colorectal cancer cells; indoleamine 2; interferon-γ; signal transducer and activator of transcription 1

Year:  2012        PMID: 23741252      PMCID: PMC3673646          DOI: 10.3892/ol.2012.761

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  33 in total

1.  Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma.

Authors:  Soranobu Ninomiya; Takeshi Hara; Hisashi Tsurumi; Naoe Goto; Kuniaki Saito; Mitsuru Seishima; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  Leuk Lymphoma       Date:  2012-01-11

2.  EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells.

Authors:  Masahito Shimizu; Atsuko Deguchi; Andrew K Joe; Judith F Mckoy; Hisataka Moriwaki; I Bernard Weinstein
Journal:  J Exp Ther Oncol       Date:  2005

Review 3.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

4.  Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Soranobu Ninomiya; Takeshi Hara; Hisashi Tsurumi; Masato Hoshi; Nobuhiro Kanemura; Naoe Goto; Senji Kasahara; Masahito Shimizu; Hiroyasu Ito; Kuniaki Saito; Yoshinobu Hirose; Tetsuya Yamada; Takeshi Takahashi; Mitsuru Seishima; Tsuyoshi Takami; Hisataka Moriwaki
Journal:  Ann Hematol       Date:  2010-10-12       Impact factor: 3.673

5.  Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase.

Authors:  Kengo Ogawa; Takeshi Hara; Masahito Shimizu; Soranobu Ninomiya; Junji Nagano; Hiroyasu Sakai; Masato Hoshi; Hiroyasu Ito; Hisashi Tsurumi; Kuniaki Saito; Mitsuru Seishima; Takuji Tanaka; Hisataka Moriwaki
Journal:  Cancer Sci       Date:  2012-03-06       Impact factor: 6.716

6.  Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Authors:  Holly K Koblish; Michael J Hansbury; Kevin J Bowman; Gengjie Yang; Claire L Neilan; Patrick J Haley; Timothy C Burn; Paul Waeltz; Richard B Sparks; Eddy W Yue; Andrew P Combs; Peggy A Scherle; Kris Vaddi; Jordan S Fridman
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

7.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

Review 8.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

9.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

Authors:  Gerald Brandacher; Alexander Perathoner; Ruth Ladurner; Stefan Schneeberger; Peter Obrist; Christiana Winkler; Ernst R Werner; Gabriele Werner-Felmayer; Helmut G Weiss; Georg Göbel; Raimund Margreiter; Alfred Königsrainer; Dietmar Fuchs; Albert Amberger
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

10.  (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.

Authors:  Yohei Shirakami; Masahito Shimizu; Seiji Adachi; Hiroyasu Sakai; Takayuki Nakagawa; Yoichi Yasuda; Hisashi Tsurumi; Yukihiko Hara; Hisataka Moriwaki
Journal:  Cancer Sci       Date:  2009-06-04       Impact factor: 6.716

View more
  17 in total

Review 1.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

2.  Green tea polyphenol EGCG suppresses osteosarcoma cell growth through upregulating miR-1.

Authors:  Kewei Zhu; Wanchun Wang
Journal:  Tumour Biol       Date:  2015-10-24

3.  Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice.

Authors:  Thomas W Hoffmann; Hang-Phuong Pham; Chantal Bridonneau; Camille Aubry; Bruno Lamas; Camille Martin-Gallausiaux; Marco Moroldo; Dominique Rainteau; Nicolas Lapaque; Adrien Six; Mathias L Richard; Emilie Fargier; Marie-Emmanuelle Le Guern; Philippe Langella; Harry Sokol
Journal:  ISME J       Date:  2015-07-28       Impact factor: 10.302

Review 4.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 5.  A multi-targeted approach to suppress tumor-promoting inflammation.

Authors:  Abbas K Samadi; Alan Bilsland; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Anupam Bishayee; Asfar S Azmi; Bal L Lokeshwar; Brendan Grue; Carolina Panis; Chandra S Boosani; Deepak Poudyal; Diana M Stafforini; Dipita Bhakta; Elena Niccolai; Gunjan Guha; H P Vasantha Rupasinghe; Hiromasa Fujii; Kanya Honoki; Kapil Mehta; Katia Aquilano; Leroy Lowe; Lorne J Hofseth; Luigi Ricciardiello; Maria Rosa Ciriolo; Neetu Singh; Richard L Whelan; Rupesh Chaturvedi; S Salman Ashraf; H M C Shantha Kumara; Somaira Nowsheen; Sulma I Mohammed; W Nicol Keith; William G Helferich; Xujuan Yang
Journal:  Semin Cancer Biol       Date:  2015-05-05       Impact factor: 15.707

6.  The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis.

Authors:  Yuhei Shibata; Takeshi Hara; Junji Nagano; Nobuhiko Nakamura; Tomohiko Ohno; Soranobu Ninomiya; Hiroyasu Ito; Takuji Tanaka; Kuniaki Saito; Mitsuru Seishima; Masahito Shimizu; Hisataka Moriwaki; Hisashi Tsurumi
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

7.  Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity.

Authors:  Vikrant Borse; Raheem F H Al Aameri; Kelly Sheehan; Sandeep Sheth; Tejbeer Kaur; Debashree Mukherjea; Srinivasan Tupal; Michelle Lowy; Sumana Ghosh; Asmita Dhukhwa; Puspanjali Bhatta; Leonard P Rybak; Vickram Ramkumar
Journal:  Cell Death Dis       Date:  2017-07-13       Impact factor: 8.469

Review 8.  Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors.

Authors:  Bilal Zulfiqar; Amnah Mahroo; Kaenat Nasir; Rai Khalid Farooq; Nasir Jalal; Muhammad Usman Rashid; Kashif Asghar
Journal:  Onco Targets Ther       Date:  2017-01-21       Impact factor: 4.147

Review 9.  Polyphenols of the Mediterranean Diet and Their Metabolites in the Prevention of Colorectal Cancer.

Authors:  Aline Yammine; Amira Namsi; Dominique Vervandier-Fasseur; John J Mackrill; Gérard Lizard; Norbert Latruffe
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

10.  Tryptophan: 'essential' for the pathogenesis of irritable bowel syndrome?

Authors:  Arnold Berstad; Jan Raa; Jørgen Valeur
Journal:  Scand J Gastroenterol       Date:  2014-07-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.